Zevalin Kit
Product Images NDC 72893-007

9 FDA label images from Acrotech Biopharma Inc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Zevalin (NDC 72893-007). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Acrotech Biopharma Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Calculate Per Rcp (Image 02)

Calculate Per Rcp (Image 02)
An image showing a formula to calculate percentage RCP, expressed as CPM bottom half divided by the sum of CPM bottom half and CPM top half, multiplied by 100. The formula appears handwritten or typeset in a simple layout.*
FDA Label Image

Study 4: Kaplan-meier Estimator For Investigator-assessed Progression Free Survival Time (Image 03)

Study 4: Kaplan-meier Estimator For Investigator-assessed Progression Free Survival Time (Image 03)
A Kaplan-Meier survival curve chart titled 'ITT Population' showing progression-free survival (PFS) over time up to 72 months from randomization. The y-axis represents the percentage of subjects without event (%), and the x-axis shows PFS time in months. Two groups are compared: Control (open squares) and Zevalin (solid circles). The chart includes a legend and numbers of subjects at risk for each group at various time points.*
FDA Label Image

Image-04 (Image 04)

Image-04 (Image 04)
Label for Zevalin Formulation Buffer, a 10 mL kit component containing human albumin 750 mg and various salts including sodium chloride, sodium phosphate dibasic dodecahydrate, pentetic acid, potassium phosphate monobasic, and potassium chloride. Manufactured for Acrotech Biopharma LLC, East Windsor, NJ. Not for direct administration, sterile and non-pyrogenic.*
FDA Label Image

Sodium Acetate (Image 05)

Sodium Acetate (Image 05)
Label for Sodium Acetate 50 mM / 2 mL vial for Zevalin kit by Acrotech Biopharma Inc. The label states it is sterile, non-pyrogenic, and not for direct administration. Includes a QR code and manufacturer address in East Windsor, NJ.*
FDA Label Image

Ibritumomab Tiuxetan (Image 06)

Ibritumomab Tiuxetan (Image 06)
Zevalin ibritumomab tiuxetan kit label showing a 3.2 mg dose in 2 mL (1.6 mg/mL). The label states it is Rx only, single-dose, sterile, non-pyrogenic, and must be diluted with supplied components prior to administration. Manufactured for Acrotech Biopharma LLC, East Windsor, NJ. Includes barcode and license information.*
FDA Label Image

Reaction Vial For Zevalin (Image 07)

Reaction Vial For Zevalin (Image 07)
Packaging label for a Reaction Vial used with Zevalin (ibritumomab tiuxetan) kit. The label indicates the vial is empty, sterile, and non-pyrogenic, with a caution that it is not for direct administration. The label includes a yellow circle with the symbol for yttrium-90 (90 Y) and states it is Rx only. Manufactured for Acrotech Biopharma LLC, East Windsor, NJ.*
FDA Label Image

90y-ibritumomab Tiuxetan (Image 08)

90y-ibritumomab Tiuxetan (Image 08)
Label for Zevalin ibritumomab tiuxetan kit showing patient-specific information fields including Activity (mCi, MBq), Kit Lot, Volume (mL), Time prepared, and Date prepared. It includes storage instructions (2°-8°C) and use within 8 hours of preparation. Labeler is Acrotech Biopharma LLC, East Windsor, NJ.*
FDA Label Image

Carton (Zevalin (Ibritumomab Tiuxetan))

Carton (Zevalin (Ibritumomab Tiuxetan))
Packaging label for Zevalin (ibritumomab tiuxetan) kit for preparation of Yttrium-90 radiolabeled product. The carton highlights a 90Y symbol indicating Yttrium-90, with instructions for intravenous use only. Labeler is Acrotech Biopharma Inc. The label provides contents including vials for use in preparation and storage instructions.*
FDA Label Image

Zevalin Dosing Schedule (Zevalin Dosing Schedule)

Zevalin Dosing Schedule (Zevalin Dosing Schedule)
An instructional diagram detailing infusion guidelines for Zevalin (ibritumomab tiuxetan) KIT. It shows the timing and dosage for IV infusion of rituximab on Day 1 and Days 7, 8, or 9, followed within 4 hours by Y-90 Zevalin infusion over 10 minutes with dose specifications based on platelet count. It also includes safety warnings about platelet counts and maximum allowable dose limits.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.